Composition, form of production and packaging
Powder for solution for injection from almost white to slightly yellow.
1 f.
cefotaxime sodium salt 250 mg
Vials with a volume of 7.5 ml (1) - packs of cardboard.
Powder for solution for injection from almost white to slightly yellow.
1 f.
cefotaxime sodium salt 500 mg
Vials with a volume of 7.5 ml (1) - packs of cardboard.
Powder for solution for injection from almost white to slightly yellow.
1 f.
cefotaxime sodium salt 1 g
Glass bottles with a volume of 10 ml (1) - boxes made of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2008.
PHARMACHOLOGIC EFFECT
Semisynthetic antibiotic group of third generation cephalosporins for parenteral use.
It is bactericidal. Has a wide range of action. Resistant to the action of most ОІ-lactamases.
Highly active against gram-negative microorganisms resistant to other antibiotics: Escherichia coli, Citrobacter diversus, Proteus mirabilis, Proteus indole, Providencia spp., Klebsiella spp., Serratia spp., Some strains of Pseudomonas spp., Haemophilus influenzae. Less active against gram-positive cocci, mainly staphylococci.
PHARMACOKINETICS
Suction
After the / m introduction is absorbed quickly. C max cefotaxime in plasma is achieved 0.5 h after injection. Bactericidal concentration in the blood remains more than 12 hours.
Distribution
Cefotaxime penetrates well into tissues and body fluids; is found in effective concentrations in the pleural, peritoneal, synovial fluids. Penetrates through the BBB.
Metabolism and excretion
Cefotaxime is biotransformed in the body with the formation of an active metabolite.
It is excreted in the urine: 30% - unchanged and about 20% - in the form of a metabolite. Partially excreted with bile.
INDICATIONS
Treatment of infectious-inflammatory diseases caused by microorganisms sensitive to the preparation:
- respiratory tract infections;
- Urinary tract infection, kidney infection;
- infection of ENT organs;
- septicemia;
- endocarditis;
- meningitis;
- skin and soft tissue infections;
- infections of bones and joints;
- intra-abdominal infections (including peritonitis);
- gynecological infections, gonorrhea;
- wound and burn infections.
DOSING MODE
The drug is administered in / m (deep), / in struyno (slowly for 3-5 minutes) or iv in drip (for 50-60 minutes).
Adults and children over 12 years of age, the drug is prescribed in a dose of 1 g every 12 hours. In severe infections, the dose is increased to 3-4 g / day (1 g 3-4 times / day). The maximum daily dose is 12 g.
Children younger than 12 years (including newborns), the drug is prescribed in a dose of 50-100 mg / kg body weight / day with intervals between administrations from 6 to 12 hours. For premature infants, the daily dose should not exceed 50 mg / kg body weight .
At the expressed infringements of function of kidneys (KK? 10 ml / mines) the daily dose of a preparation reduce in 2 times.
Rules for the preparation of injectable solutions
To prepare a solution for intravenous administration, dissolve 250 mg or 500 mg of the drug in 2 ml (respectively 1 g in 4 ml) of sterile water for injection. A 1% solution of lidocaine can also be used as the solvent in the case of the / m administration.
For intravenous administration 500 mg - 1 g of cefotaxime is dissolved in 4 ml (2 g in 10 ml) of sterile water for injection.
For intravenous drip injection, dissolve 2 g of the drug in 100 ml of a 0.9% solution of sodium chloride or 5% solution of dextrose.
SIDE EFFECT
Allergic reactions: skin rash, fever, anaphylactic shock.
On the part of the digestive system: dyspepsia, impaired functional tests of the liver, increasing the level of alkaline phosphatase; rarely - pseudomembranous colitis.
From the hemopoietic system: eosinophilia, leukopenia, neutropenia, agranulocytosis, hemolytic anemia.
Other: increased urinary nitrogen in the urine, increased body temperature.
Local reactions: pain, hyperemia, edema at the injection site.
CONTRAINDICATIONS
- Children's age to 2.5 years (for the / m introduction);
- Hypersensitivity to cephalosporins.
With caution should prescribe the drug for violations of the liver and kidneys.
PREGNANCY AND LACTATION
The use of the drug during pregnancy is possible only if the intended benefit to the mother exceeds the potential risk to the fetus.
Cefotaxime excreted in breast milk, so if you need to use Liforan during lactation should stop breastfeeding.
APPLICATION FOR FUNCTIONS OF THE LIVER
With caution should prescribe the drug for violations of kidney function. At the expressed infringements of function of kidneys (KK? 10 ml / mines) the daily dose of a preparation reduce in 2 times.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
With caution should prescribe the drug for violations of liver function.
SPECIAL INSTRUCTIONS
Before the appointment of Liforan, it is necessary to collect an allergic medical history, especially with reference to allergic reactions to beta-lactam antibiotics. There is a cross-allergy between penicillins and cephalosporins. In patients who have a history of indicating allergic reactions to penicillin, the drug is used with extreme caution.
When there are reactions of hypersensitivity (which are severe and can even lead to death), the drug is canceled.
With a duration of treatment with the drug for more than 10 days, it is necessary to monitor the picture of peripheral blood.
With simultaneous use of Liforan and potentially nephrotoxic drugs (aminoglycoside antibiotics, diuretics), it is necessary to monitor the kidney function (due to the danger of nephrotoxic action).
During the treatment period, a false positive test of Coombs may occur.
It is possible to develop false positive results in determining the glucose level in the urine by non-enzyme methods (for example, the Benedict method).
OVERDOSE
Data on cases of an overdose of Liforan are not available.
DRUG INTERACTION
With simultaneous application, Liphoran can potentiate the toxic effect of drugs that have a nephrotoxic effect.
Pharmaceutical interaction
The solution of Liforan is incompatible with solutions of other antibiotics in one syringe or dropper.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a dry, protected from light, out of reach of children at a temperature of no higher than 25 В° C. Shelf life - 3 years.
